atorvastatin has been researched along with Osteoporosis, Postmenopausal in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C | 1 |
| Cui, L; Fu, Z; Huang, J; Lee, WY; Li, G; Liang, Y; Lin, S; Qin, L; Sun, Y; Wu, H; Wu, T; Xu, L | 1 |
| Bertacco, E; Buso, R; Di Virgilio, R; Fadini, GP; Faggin, E; Palmosi, T; Pauletto, P; Plebani, M; Puato, M; Rattazzi, M; Zaninotto, M | 1 |
| Barut, A; Sarikaya, S; Tanriverdi, HA | 1 |
| Arikan, O; Dokmetas, S; Yilmaz, A | 1 |
| Epstein, M; Laskey, R; Leary, E; Lowe, W; Reed, D; Zuckerman, A | 1 |
1 review(s) available for atorvastatin and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.
Topics: Alendronate; Alkaline Phosphatase; Atorvastatin; Bone Density; Bone Density Conservation Agents; Diabetes Mellitus; Female; Humans; Osteocalcin; Osteoporosis; Osteoporosis, Postmenopausal | 2022 |
4 trial(s) available for atorvastatin and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Atorvastatin Reduces Circulating Osteoprogenitor Cells and T-Cell RANKL Expression in Osteoporotic Women: Implications for the Bone-Vascular Axis.
Topics: Aged; Atorvastatin; Biomarkers; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Jurkat Cells; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Stem Cells; T-Lymphocytes; Time Factors; Treatment Outcome | 2016 |
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Pyrroles; Risedronic Acid | 2005 |
Effects of statins on bone mineral density.
Topics: Anticholesteremic Agents; Atorvastatin; Bone Density; Calcium; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Prospective Studies; Pyrroles; Turkey | 2006 |
Atorvastatin does not induce glomerular or tubular dysfunction even at high doses.
Topics: Acetylglucosaminidase; Adult; Aged; Atorvastatin; beta 2-Microglobulin; Creatinine; Cystatin C; Cystatins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Kidney Tubules; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Pyrroles | 2007 |
1 other study(ies) available for atorvastatin and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats.
Topics: Animal Feed; Animals; Atorvastatin; Bone Density; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; X-Ray Microtomography | 2015 |